ATI RN
WGU Pathophysiology Final Exam
1. A newborn is diagnosed with congenital intrinsic factor deficiency. Which of the following types of anemia will the nurse see documented on the chart?
- A. Iron deficiency anemia
- B. Sideroblastic anemia
- C. Pernicious anemia
- D. Hemolytic anemia
Correct answer: C
Rationale: The correct answer is C, Pernicious anemia. Pernicious anemia is associated with a congenital intrinsic factor deficiency, leading to the impaired absorption of vitamin B12. Iron deficiency anemia (Choice A) is not directly related to intrinsic factor deficiency. Sideroblastic anemia (Choice B) is characterized by defective iron uptake by developing erythrocytes and is not linked to intrinsic factor deficiency. Hemolytic anemia (Choice D) involves the premature destruction of red blood cells and is not specifically associated with intrinsic factor deficiency.
2. A male patient receiving androgen therapy is concerned about the risk of prostate cancer. What should the nurse explain regarding this risk?
- A. Finasteride has been shown to lower the risk of developing prostate cancer.
- B. Finasteride does not affect the risk of prostate cancer.
- C. Finasteride may increase the risk of developing prostate cancer, so regular screenings are recommended.
- D. Finasteride has no effect on the risk of prostate cancer, so regular screenings are unnecessary.
Correct answer: A
Rationale: The correct answer is A. Finasteride has been shown to lower the risk of developing prostate cancer. However, regular screenings are still recommended to monitor for any potential issues. Choice B is incorrect because finasteride has been associated with a reduced risk of developing prostate cancer. Choice C is incorrect as finasteride is not known to increase the risk of prostate cancer; in fact, it has shown a protective effect. Choice D is incorrect because while finasteride may lower the risk of prostate cancer, regular screenings are still necessary to ensure early detection and treatment if needed.
3. What long-term risks should the nurse discuss with a patient being treated with hormone replacement therapy (HRT) for menopausal symptoms?
- A. HRT may increase the risk of cardiovascular events and breast cancer.
- B. HRT may decrease the risk of osteoporosis.
- C. HRT may improve mood and energy levels.
- D. HRT may increase the risk of venous thromboembolism.
Correct answer: A
Rationale: The correct answer is A. Long-term hormone replacement therapy (HRT) is associated with increased risks of cardiovascular events and breast cancer. These risks should be discussed with the patient to ensure they are aware of the potential adverse effects. Choice B is incorrect because HRT does not decrease the risk of osteoporosis; in fact, it has been linked to an increased risk of this condition. Choice C is incorrect as while HRT may have positive effects on mood and energy levels for some individuals, the focus here is on the long-term risks that need to be addressed. Choice D is incorrect as HRT is indeed associated with an increased risk of venous thromboembolism, but the primary focus of the question is on cardiovascular events and breast cancer.
4. A patient taking oral contraceptives reports breakthrough bleeding. What should the nurse assess in this patient?
- A. Adherence to the medication schedule
- B. The possibility of pregnancy
- C. The need for an increased dosage
- D. The effectiveness of the current oral contraceptive
Correct answer: A
Rationale: When a patient on oral contraceptives experiences breakthrough bleeding, the nurse should assess the patient's adherence to the medication schedule. Breakthrough bleeding can be a sign of missed doses or inconsistent timing, which can decrease the effectiveness of oral contraceptives. Assessing the patient's adherence helps in ensuring proper use of the medication. Choices B, C, and D are incorrect because breakthrough bleeding is more likely related to adherence issues rather than pregnancy, the need for increased dosage, or the effectiveness of the current oral contraceptive.
5. A patient with endometriosis is prescribed medroxyprogesterone acetate (Provera). What should the nurse include in the patient education?
- A. Medroxyprogesterone should be taken at the same time each day to maintain consistent hormone levels.
- B. Medroxyprogesterone can be taken with food to reduce gastrointestinal upset.
- C. Medroxyprogesterone should be discontinued if side effects occur.
- D. Medroxyprogesterone should be taken once a week to maintain effectiveness.
Correct answer: A
Rationale: When educating a patient with endometriosis who is prescribed medroxyprogesterone acetate (Provera), the nurse should emphasize the importance of taking the medication at the same time each day. This helps maintain consistent hormone levels and ensures the effectiveness of the treatment. Option A is correct. Option B is incorrect because medroxyprogesterone should be taken consistently, regardless of food intake. Option C is incorrect because discontinuing the medication without consulting a healthcare provider can be harmful. Option D is incorrect because medroxyprogesterone is typically taken daily, not weekly, for the treatment of endometriosis.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access